Global Pharma Companies Begin Conducting Comparative Effectiveness Research During Phase 3 of Product Development RESEARCH TRIANGLE PARK, NC--(Marketwired - June 26, 2017) - Research from global market access teams found that pharmaceutical and medical device companies often wait until Phase 3 or later to...

Global Pharmaceutical Comparative Effectiveness Research Teams Increasing Budgets RESEARCH TRIANGLE PARK, NC--(Marketwired - July 21, 2016) - Pharmaceutical companies' comparative effectiveness (CER) managers indicate upward trends in spending from an average $5 million budget,...

Spend on HEOR Studies Expected to Grow at 9.7% Through 2020 CARY, NC--(Marketwired - July 19, 2016) - Industry Standard Research has released a new report, "Late Phase Study Trends and Market Outlook (2016-2020)," containing findings focused on current...

Drug Companies Spend an Average $13,000 per Patient on Comparative Effectiveness Research in Phase IV RESEARCH TRIANGLE PARK, NC--(Marketwire - Aug 9, 2011) - The cost of running a comparative effectiveness trial is $13,087 per patient during Phase IV, according to a study by Cutting Edge...

Cutting Edge Information Analyzes How Drug Makers Embrace Comparative Effectiveness Research (CER) RESEARCH TRIANGLE PARK, NC--(Marketwire - October 20, 2009) - A higher percentage of companies are using Comparative Effectiveness Research to help with pricing and reimbursement decisions, according...